{
    "clinical_study": {
        "@rank": "142920", 
        "acronym": "VERIFY", 
        "arm_group": [
            {
                "arm_group_label": "1 Vandetanib 300 mg", 
                "arm_group_type": "Experimental", 
                "description": "vandetanib clinical trials tablets"
            }, 
            {
                "arm_group_label": "2 Placebo 300 mg", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo to match vandetanib tablet"
            }
        ], 
        "brief_summary": {
            "textblock": "The Study is designed to assess the efficacy, safety and tolerability of vandetanib 300 mg\n      daily in patients with differentiated thyroid cancer that is either locally advanced or\n      metastatic who are refractory or unsuitable for radioiodine (RAI) therapy."
        }, 
        "brief_title": "Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Differentiated Thyroid Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Thyroid Neoplasms", 
                "Thyroid Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the\n      Efficacy and Safety of Vandetanib (CAPRELSA) 300 mg in Patients with  Differentiated Thyroid\n      Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for\n      Radioiodine (RAI) Therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provision of informed consent to participate in the study as well as provision of\n             informed consent to provide a sample of a previously obtained archival tumour biopsy.\n\n          -  Female or male aged 18 years and older with previously confirmed histological\n             diagnosis of locally advanced or metastatic differentiated (excluding minimally\n             invasive follicular) thyroid cancer not amenable to surgical resection, external beam\n             radiotherapy or local therapy.\n\n          -  Measurable disease defined as at least one lesion, not irradiated within 12 weeks of\n             the date of randomisation, that can be accurately measured at baseline.\n\n          -  Patients must have progression and be RAI-refractory/resistant or unsuitable for RAI.\n\n          -  TSH suppression below 0.5 mU/L is required.\n\n        Exclusion Criteria:\n\n          -  Risk of prolonged QTc as defined by history of QT prolongation; current therapy with\n             any medication known to be associated with Torsades de Pointes or prolongation of QT;\n             congenital long QT syndrome.\n\n          -  Previous therapy with approved or investigational tyrosine kinase or anti-VEGF\n             receptor inhibitors or targeted therapies (e.g. multi-targeted kinase inhibitors such\n             as sorafenib, AMG-706, sunitinib, pazopanib, lenvatinib).\n\n          -  RAI therapy within 12 weeks prior to first dose of study drug, and radiation therapy\n             other than RAI, including external beam, if not completed prior to randomisation.\n\n          -  Inadequate organ function as defined by elevated ALT, AST, ALP or bilirubin; or\n             creatinine clearance <50 ml/min."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "255", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01876784", 
            "org_study_id": "D4203C00011", 
            "secondary_id": "2013-000422-58"
        }, 
        "intervention": [
            {
                "arm_group_label": "1 Vandetanib 300 mg", 
                "description": "300 mg (3 x 100 mg tablets) will be dosed orally, once daily", 
                "intervention_name": "vandetanib", 
                "intervention_type": "Drug", 
                "other_name": "CAPRELSA"
            }, 
            {
                "arm_group_label": "2 Placebo 300 mg", 
                "description": "300 mg (3 x 100 mg tablets) will be dosed orally, once daily", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug", 
                "other_name": "CAPRELSA placebo"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "vandetanib, AZD 6474, Differentiated Thyroid Cancer", 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Little Rock", 
                        "country": "United States", 
                        "state": "Arkansas"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torrance", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Suspended"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegre", 
                        "country": "Brazil"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ribeir\u00e3o Preto", 
                        "country": "Brazil"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rio de Janeiro", 
                        "country": "Brazil"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "S\u00e3o Jos\u00e9 do Rio Preto", 
                        "country": "Brazil"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "S\u00e3o Paulo", 
                        "country": "Brazil"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changchun", 
                        "country": "China"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Huangzhou", 
                        "country": "China"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Olomouc", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Odense", 
                        "country": "Denmark"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Angers Cedex 01", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux Cedex", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Caen Cedex 5", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris Cedex 13", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif Cedex", 
                        "country": "France"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Catania", 
                        "country": "Italy"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pisa", 
                        "country": "Italy"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Siena", 
                        "country": "Italy"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bunkyo-ku", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukushima-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kashiwa-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kobe-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koto-ku", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Matsumoto-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagasaki-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagoya-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Niigata-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shinjuku-ku", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokohama-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gliwice", 
                        "country": "Poland"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kielce", 
                        "country": "Poland"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pozna\u0144", 
                        "country": "Poland"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warszawa", 
                        "country": "Poland"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zgierz", 
                        "country": "Poland"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barnaul", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Obninsk", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gerona", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hospitalet de Llobregat(Barcel", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lund", 
                        "country": "Sweden"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Brazil", 
                "China", 
                "Czech Republic", 
                "Denmark", 
                "France", 
                "Italy", 
                "Japan", 
                "Poland", 
                "Russian Federation", 
                "Spain", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Ian Smith, MSD"
        }, 
        "overall_contact_backup": {
            "email": "astrazeneca@emergingmed.com", 
            "last_name": "AstraZeneca Cancer Study Locator Service -", 
            "phone": "877-400-4656"
        }, 
        "overall_official": [
            {
                "affiliation": "Department of Nuclear Medicine and Endocrine Oncology, Institut Gustave Roussy, 94805 Villejuif, France", 
                "last_name": "Martin Schlumberger, PROFESSOR, M.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "11G34, Mereside, Alderley Park, Macclesfield, Cheshire, England", 
                "last_name": "Ian Smith, M.D., PHD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Italy: The Italian Medicines Agency", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Sweden: Medical Products Agency", 
                "China: Food and Drug Administration", 
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Spain: Spanish Agency of Medicines", 
                "Czech Republic: State Institute for Drug Control", 
                "Brazil: National Health Surveillance Agency", 
                "United States: Food and Drug Administration", 
                "Denmark: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Once 155 progression events have occurred.", 
            "measure": "Determination of the efficacy (as assessed by progression-free survival) of vandetanib when compared to placebo in the patient population", 
            "safety_issue": "No", 
            "time_frame": "Estimated time frame up to 25.5 months (18 months recruitment period plus 7.5 months follow-up). RECIST measurements taken every 12 weeks from randomization"
        }, 
        "removed_countries": {
            "country": [
                "United Kingdom", 
                "Hungary", 
                "Belgium", 
                "Romania", 
                "Germany"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01876784"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Once 155 progression events have occurred.", 
                "measure": "Determination of the efficacy of vandetanib when compared to placebo in the patient population as assessed by efficacy variables including duration of response.", 
                "safety_issue": "No", 
                "time_frame": "Estimated time frame up to 25.5 months (18 months recruitment period plus 7.5 months follow up). RECIST measurements taken every 12 weeks from randomization"
            }, 
            {
                "description": "Once 155 progression events have occured.", 
                "measure": "Demonstration of an improvement in time to worsening of pain in patients treated with vandetanib when compared to placebo in the patient population.", 
                "safety_issue": "No", 
                "time_frame": "Patient assessments at baseline, week 4, 8, 12 and then 12 weekly thereafter, assess up to 25.5 months"
            }, 
            {
                "description": "Once 155 progression events have occurred.", 
                "measure": "Evaluation of the safety and tolerability of vandetanib treatment in the patient population by assessment of adverse events, vital signs, laboratory parameters and electrocardiography.", 
                "safety_issue": "Yes", 
                "time_frame": "Safety assessments at baseline, Weeks 1, 2, 4, 8, 12 and then 12 weekly thereafter"
            }, 
            {
                "description": "Once 155 progression events have occurred.", 
                "measure": "Determination of the efficacy of vandetanib when compared to placebo in the patient population as assessed by efficacy variables including objective response rate.", 
                "safety_issue": "No", 
                "time_frame": "Estimated time frame up to 25.5 months (18 months recruitment period plus 7.5 months follow up). RECIST measurements taken every 12 weeks from randomization"
            }, 
            {
                "description": "Once 155 progression events have occurred.", 
                "measure": "Determination of the efficacy of vandetanib when compared to placebo in the patient population as assessed by efficacy variables including change in tumour size", 
                "safety_issue": "No", 
                "time_frame": "Assessed tumour size at screening, Weeks 7, 8 and then 12 weekly thereafter and at Discontinuation visit, estimated time frame at 25.5 months."
            }, 
            {
                "description": "Once 155 progression events have occurred and when 50% of randomized patients have died due to any cause.", 
                "measure": "Determination of the efficacy of vandetanib when compared to placebo in the patient population as assessed by efficacy variables including overall survival", 
                "safety_issue": "No", 
                "time_frame": "Estimated time frame at 20 months after initial 25.5 months."
            }, 
            {
                "description": "Estimated time frame up to 155 progression events have occured or up to individual progression of patient.", 
                "measure": "Evaluation of the pharmacokinetics of vandetanib in the patient population by assessment of V/F.", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 4-6 hours post-dose at Weeks 1, 2, 4, 8, 12 and then 12 weekly thereafter until discontinuation."
            }, 
            {
                "description": "Estimated time frame up to 155 progression events have occured or up to individual progression of patient.", 
                "measure": "Evaluation of the pharmacokinetics of vandetanib in the patient population by assessment of Cmax", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 4-6 hours post-dose at Weeks 1, 2, 4, 8, 12 and then 12 weekly thereafter until discontinuation."
            }, 
            {
                "description": "Estimated time frame up to 155 progression events have occured or up to individual progression of patient.", 
                "measure": "Evaluation of the pharmacokinetics of vandetanib in the patient population by assessment of AUCss", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 4-6 hours post-dose at Weeks 1, 2, 4, 8, 12 and then 12 weekly thereafter until discontinuation."
            }, 
            {
                "description": "Estimated time frame up to 155 progression events have occured or up to individual progression of patient.", 
                "measure": "Evaluation of the pharmacokinetics of vandetanib in the patient population by assessment of CL/F", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 4-6 hours post-dose at Weeks 1, 2, 4, 8, 12 and then 12 weekly thereafter until discontinuation."
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}